NASDAQ$HOLX

Hologic Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Revenue and earnings exceeded prior guidance, with strong growth across all core franchises.

Hologic reported a decrease in revenue by 28.5% to $1,026.5 million, primarily due to lower COVID-19 assay sales. Excluding COVID-19 revenues, total organic revenue grew by 20.2%. The company's GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance. Hologic raised its fiscal year 2023 revenue and EPS guidance.

  • Revenue decreased by 28.5% to $1,026.5 million, but exceeded prior guidance.
  • Excluding COVID-19 revenues, total organic revenue grew by 20.2%.
  • GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance.
  • The company raised its fiscal year 2023 revenue and EPS guidance.

Headline financials

Total Revenue

$1.03B

Previous: $1.44B-28.5%
EPS (adj)

$1.06

Previous: $2.07-48.8%
GAAP Gross Margin

57.1%

No prior period
Non-GAAP Gross Margin

62.1%

No prior period
Non-GAAP Operating Margin

31.3%

No prior period
Non-GAAP Net Margin

25.9%

No prior period
Net Income

$219M

Previous: $456M-52.1%
Operating Income

$272M

Previous: $594M-54.2%
Gross Profit

$586M

Previous: $947M-38.1%
Cash & Equivalents

$2.58B

Previous: $2.29B+12.7%
Total Assets

$9.45B

Previous: $9.51B-0.7%
Stock-Based Comp

$23.2M

Previous: $17.8M+30.3%

Revenue & EPS history

Hologic · Revenue · Quarterly

$1.03B

Q2 2023-28.5%vs Q2 2022
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

Hologic · $850M total across 2 segments · Q2 2023

  • Diagnostics
    $465M
  • Breast Health
    $385M

Forward guidance

Hologic raised its full-year guidance for both revenue and EPS, highlighting confidence in the remainder of the fiscal year despite an uncertain macro environment.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-0.5%

Avg return

Earnings day

+0.2%

Avg return

5 days after

-0.1%

Avg return

30 days after

49%

35 / 72 earnings

Positive

+12.3%

Q3 2020

Best reaction

-11.4%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-0.6%+0.7%
Q4 2025+0.1%+0.1%+0.9%
Q3 2025+2.8%+4.4%+3.3%
Q2 2025-5.6%-3.2%+8.5%
Q1 2025-10.1%-11.4%-11.3%
Q4 2024-4.3%-4.3%-6.6%
Q3 2024+4.9%+6.4%+2.2%
Q2 2024+0.3%-0.2%-3.3%
Q1 2024-2.7%-0.4%-1.1%
Q4 2023+5.7%+5.4%+0.1%
Q3 2023-5.1%-5.9%-5.4%
Q2 2023-2.4%-2.6%-8.3%
Q1 2023+3.8%+3.6%-1.1%
Q4 2022+10.8%+12.4%+13.8%
Q3 2022+1.0%+1.3%-3.4%
Q2 2022+1.2%+3.4%+9.8%
Q1 2022+4.0%+3.8%+2.4%
Q4 2021-3.3%-5.9%-0.3%
Q3 2021+2.3%+5.0%+9.7%
Q2 2021-9.1%-9.9%-13.4%
Q1 2021+1.7%+11.2%-3.3%
Q4 2020+6.6%-5.0%+1.7%
Q3 2020+12.3%+14.8%-2.8%
Q2 2020+2.9%+2.6%+8.9%
Q1 2020-0.7%-1.8%-13.7%
Q4 2019-4.0%+8.8%+10.3%
Q3 2019-1.3%-6.5%-4.1%
Q2 2019-0.1%+0.7%-5.1%
Q1 2019+0.6%-0.5%+8.6%
Q4 2018+4.9%+1.2%+3.7%
Q3 2018-3.5%-1.9%-7.5%
Q2 2018-6.9%-6.8%-3.9%
Q1 2018-6.7%-6.6%-2.2%
Q4 2017+0.4%+2.9%+8.1%
Q3 2017-9.3%-11.3%-12.5%
Q2 2017-4.3%-5.1%-2.0%
Q1 2017-2.6%-2.9%+1.8%
Q4 2016+4.3%+8.5%+6.3%
Q3 2016+3.9%+5.8%+5.3%
Q2 2016-10.0%
Q1 2016-9.2%
Q4 2015+0.6%
Q3 2015+8.6%
Q2 2015+2.1%
Q1 2015+5.1%
Q4 2014-1.7%
Q3 2014+2.1%
Q2 2014+8.1%
Q1 2014-5.9%
Q4 2013-6.9%
Q3 2013-0.2%
Q2 2013+0.1%
Q1 2013-4.1%
Q4 2012-0.3%
Q3 2012-0.4%
Q2 2012-11.4%
Q1 2012+5.2%
Q4 2011-4.0%
Q3 2011-3.9%
Q2 2011-0.6%
Q1 2011+0.0%
Q4 2010+1.2%
Q3 2010+1.2%
Q2 2010-2.6%
Q1 2009-2.8%
Q1 2010-1.1%
Q2 2009+2.9%
Q4 2007+2.9%
Q4 2009+2.9%
Q3 2009-3.0%
Q3 2008-3.0%
Q4 2008-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro